The every-other-month intra-ocular injection shows a reduction in lesion growth that increases over time. The ocular formulation of the drug, previously approved for paroxysmal nocturnal hemoglobinuria, should be available in specialty pharmacies in March 2023.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS